T
Toshinari Yamasaki
Researcher at University of Texas Southwestern Medical Center
Publications - 5
Citations - 1111
Toshinari Yamasaki is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Exome & Downregulation and upregulation. The author has an hindex of 5, co-authored 5 publications receiving 969 citations. Previous affiliations of Toshinari Yamasaki include University of Texas at Dallas.
Papers
More filters
Journal ArticleDOI
BAP1 loss defines a new class of renal cell carcinoma
Samuel Peña-Llopis,Silvia Vega-Rubin-de-Celis,Silvia Vega-Rubin-de-Celis,Arnold Liao,Nan Leng,Andrea Pavia-Jimenez,Andrea Pavia-Jimenez,Shanshan Wang,Shanshan Wang,Toshinari Yamasaki,Toshinari Yamasaki,Leah Zhrebker,Leah Zhrebker,Sharanya Sivanand,Sharanya Sivanand,Patrick Spence,Patrick Spence,Lisa N. Kinch,Tina Hambuch,Suneer Jain,Yair Lotan,Vitaly Margulis,Arthur I. Sagalowsky,Pia Banerji Summerour,Wareef Kabbani,S. W Wendy Wong,Nick V. Grishin,Marc Laurent,Xian Jin Xie,Christian D. Haudenschild,Mark T. Ross,David R. Bentley,Payal Kapur,James Brugarolas +33 more
TL;DR: The results establish the foundation for an integrated pathological and molecular genetic classification of RCC, paving the way for subtype-specific treatments exploiting genetic vulnerabilities.
Journal ArticleDOI
A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
Sharanya Sivanand,Samuel Peña-Llopis,Hong Zhao,Blanka Kucejova,Patrick Spence,Andrea Pavia-Jimenez,Toshinari Yamasaki,David J. McBride,Jessica Gillen,Nicholas C. Wolff,Lorraine Morlock,Yair Lotan,Ganesh V. Raj,Arthur I. Sagalowsky,Vitaly Margulis,Jeffrey A. Cadeddu,Mark T. Ross,David R. Bentley,Wareef Kabbani,Xian Jin Xie,Payal Kapur,Noelle S. Williams,James Brugarolas +22 more
TL;DR: The development and validation of a tumorgraft model of renal cell carcinoma (RCC) is described and validated and should be useful for testing other targeted drugs preclinically, given that most anticancer drugs that enter clinical trials fail to gain approval.
Journal ArticleDOI
Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma
Blanka Kucejova,Samuel Peña-Llopis,Toshinari Yamasaki,Sharanya Sivanand,Tram Anh T. Tran,Shane Alexander,Nicholas C. Wolff,Yair Lotan,Xian Jin Xie,Wareef Kabbani,Payal Kapur,James Brugarolas +11 more
TL;DR: Using ccRCC-derived cell lines, it is shown that REDD1 upregulation in tumors is VHL dependent and that both Hif-1 and HIF-2 are, in a cell-type-dependent manner, recruited to, and essential for, REDD 1 induction.
Journal ArticleDOI
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC
Toshinari Yamasaki,Tram Anh T. Tran,Orhan K. Öz,Ganesh V. Raj,Roderich E. Schwarz,Ralph J. DeBerardinis,Xuewu Zhang,James Brugarolas +7 more
TL;DR: Treatment with the glycolytic inhibitor 2DG (2-deoxy-D-glucose) was not effective, and a patient with a novel germline FH mutation and de novo hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome progressing after mTORC1 inhibitor therapy died.
Journal ArticleDOI
Erratum: BAP1 loss defines a new class of renal cell carcinoma (Nature Genetics (2012) 44 (751-759))
Samuel Peña-Llopis,Silvia Vega-Rubin-de-Celis,Arnold Liao,Nan Leng,Andrea Pavia-Jimenez,Shanshan Wang,Toshinari Yamasaki,Leah Zhrebker,Sharanya Sivanand,Patrick Spence,Lisa N. Kinch,Tina Hambuch,Suneer Jain,Yair Lotan,Vitaly Margulis,Arthur I. Sagalowsky,Pia Banerji Summerour,Wareef Kabbani,S. W Wendy Wong,Nick V. Grishin,Marc Laurent,Xian Jin Xie,Christian D. Haudenschild,Mark T. Ross,David R. Bentley,Payal Kapur,James Brugarolas +26 more
TL;DR: In the version of this article initially published, the P value given in the abstract for the anticorrelation between BAP1 and PBRM1 mutations was given incorrectly as 9 × 10−6 instead of 3 ×10−5.